Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7296
    -0.0024 (-0.33%)
     

  • CRUDE OIL

    82.89
    -0.47 (-0.56%)
     

  • Bitcoin CAD

    87,587.75
    -3,065.26 (-3.38%)
     

  • CMC Crypto 200

    1,385.80
    -38.30 (-2.69%)
     

  • GOLD FUTURES

    2,331.10
    -11.00 (-0.47%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ

    15,712.75
    +16.11 (+0.10%)
     

  • VOLATILITY

    15.63
    -0.06 (-0.38%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6818
    -0.0018 (-0.26%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

EU in talks with Gilead to get remdesivir doses for EU countries

Reuters
Updated ·1 min read

BRUSSELS, July 1 (Reuters) - The European Commission said on Wednesday it was in negotiations with Gilead Sciences Inc to obtain doses of COVID-19 antiviral remdesivir for the 27 European Union countries.

The Commission said it took note of the announcement that the United States had secured nearly all of Gilead's projected production capacity for the next three months. Remdevisir is set to be approved for use in Europe in the coming days.

"Commissioner (Stella) Kyriakides has been in multiple discussions with the manufacturer, Gilead, including on their production capacity. The Commission is also currently in negotiations with Gilead to reserve doses of remdesivir for EU member states," a Commission spokesman said. (Reporting by Philip Blenkinsop, editing by Marine Strauss)